Receptor levels, apoptosis, and proliferation in MC cultures
| Cells . | Assay . | IL-3 . | SCF . | IL-3 + SCF . | |||
|---|---|---|---|---|---|---|---|
| Week 1 . | Week 3 . | Week 1 . | Week 3 . | Week 1 . | Week 3 . | ||
| WT | c-Kit/FcϵRI* | 23.2 ± 6.2 | 86.5 ± 4.8 | 16.5 ± 6.3 | 70.9 ± 14.2 | 28.7 ± 2.1 | 88.4 ± 9.1 |
| ATF3 | c-Kit/FcϵRI* | 17.7 ± 4.9 | 78.9 ± 11.5 | 12.0 ± 4.4 | 82.2 ± 10.3 | 32.7 ± 3.6 | 95.0 ± 2.2 |
| WT | Percentage of apoptosis | 29.2 ± 4.5 | 17.4 ± 2.8† | 10.3 ± 2.3 | 6.7 ± 0.6† | 16.7 ± 1.6 | 27.8 ± 3.4 |
| ATF3 | Percentage of apoptosis | 33.1 ± 5.8 | 66.8 ± 6.1† | 13.8 ± 3.1 | 17.4 ± 2.8† | 24.4 ± 3.8 | 33.0 ± 0.5 |
| WT | Abs 550 (MTT) | 0.58 ± 0.24† | 1.06 ± 0.08† | 0.40 ± 0.04 | 1.14 ± 0.27 | 0.46 ± 0.26† | 0.99 ± 0.19 |
| ATF3 | Abs 550 (MTT) | 0.49 ± 0.16† | ND | 0.47 ± 0.43 | 0.81 ± 0.28 | 0.56 ± 0.24† | 0.66 ± 0.27 |
| Cells . | Assay . | IL-3 . | SCF . | IL-3 + SCF . | |||
|---|---|---|---|---|---|---|---|
| Week 1 . | Week 3 . | Week 1 . | Week 3 . | Week 1 . | Week 3 . | ||
| WT | c-Kit/FcϵRI* | 23.2 ± 6.2 | 86.5 ± 4.8 | 16.5 ± 6.3 | 70.9 ± 14.2 | 28.7 ± 2.1 | 88.4 ± 9.1 |
| ATF3 | c-Kit/FcϵRI* | 17.7 ± 4.9 | 78.9 ± 11.5 | 12.0 ± 4.4 | 82.2 ± 10.3 | 32.7 ± 3.6 | 95.0 ± 2.2 |
| WT | Percentage of apoptosis | 29.2 ± 4.5 | 17.4 ± 2.8† | 10.3 ± 2.3 | 6.7 ± 0.6† | 16.7 ± 1.6 | 27.8 ± 3.4 |
| ATF3 | Percentage of apoptosis | 33.1 ± 5.8 | 66.8 ± 6.1† | 13.8 ± 3.1 | 17.4 ± 2.8† | 24.4 ± 3.8 | 33.0 ± 0.5 |
| WT | Abs 550 (MTT) | 0.58 ± 0.24† | 1.06 ± 0.08† | 0.40 ± 0.04 | 1.14 ± 0.27 | 0.46 ± 0.26† | 0.99 ± 0.19 |
| ATF3 | Abs 550 (MTT) | 0.49 ± 0.16† | ND | 0.47 ± 0.43 | 0.81 ± 0.28 | 0.56 ± 0.24† | 0.66 ± 0.27 |
Results are expressed as mean ± SE from counts of 3 separate experiments.
MC indicates mast cell; WT, wild-type; ATF, activating transcription factor; MTT, 4,5-dimethylthiazol-2-yl-3,5-diphenylformazan, thiazolyl blue formazan; and ND, not determined.
Percentage of positive cells.
P < .05 by comparison to WT cells.